Table 2.
CD47/SIRPα targeting agents investigated in AML and/or MDS.
| Molecule | Magrolimab (5F9) | TTI-621 | CC-90002 |
|---|---|---|---|
| Sponsor | Forty Seven, Inc. | Trillium therapeutics | Celgene |
| Mechanism of action | Anti-CD47 antibody, IgG4 isotype | SIRPα-Fc fusion protein. IgG1 isotype | Anti-CD47 antibody, IgG4 isotype |
| Studies in AML/MDS | Phase 1 trial of Anti-CD47 Antibody in Haematologic Malignancies (NCT02678338) Phase 1b trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies (NCT03248479) | Phase 1 trial of TTI-621 for Patients with Hematologic Malignancies and Selected Solid Tumors (NCT02663518) | Phase 1 trial of CC-90002 in Subjects with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (NCT02641002) |
| Study results | Phase 1 results reported (31) Initial Phase 1b results reported (32) | AML and MDS patients were enrolled, no AML/MDS specific data have not been reported | Phase 1 results reported (33) |
| Study status | Phase 1 trial completed Phase 1b trial ongoing | Ongoing | Terminated |
| Developmental stage | Phase 2/registrational in MDS Phase 1b in AML | Phase 1 | Discontinued in AML/MDS |